» Download Public Reports
About 200 reports
- Company report
- December 2012
- 45 pages
... Common reason for discontinuation of opioid therapy oic patients are viewed as Difficult to treat And are dissatisfied pcps welcome 1 medicine indicated for multiple causes of constipation amitiza does ...
December 2012
... With such outstanding results strengthens our chances for further development on the path to market maturity and our company S profile as a global leader in the market for epigenetic cancer compounds. In 3 addition ...
November 2012
... Launch(prostate cancer) oct. Jpmyrbetriq launch(overactive bladder) oct. Us (adult bronchial asthma, as-needed use in addition to maintenance therapy) infections) launch of quattrovac ...
November 2012
... Towards the end of 2013 phase 3a trial programme Fiasp1 demonstrated earlier onset of appearance as compared to insulin aspart No significant differences in duration of action seen between fiasp1 ...
December 2012
... And europe that evaluated halaven as a potential second-line chemotherapy for the treatment of breast cancer, the group is currently preparing for submission of applications seeking approval for additional ...
December 2012
... The strongest contributor to performance for december. The great run of the liver cancer treatment company continued to the end of 2012 with the company being officially included, due to its rise in market ...
January 2013
... It comes to cancer management, the phenomenon of quality of life is regarded as a multi-dimensional concept and it involves patients social, emotional and physical well being.7 It would be worth mentioning ...
January 2013
... Associated with juxtapid treatment may be a risk factor for progressive liver disease, including steatohepatitis and cirrhosis. Measure alt, ast, alkaline phosphatase, and total bilirubin before initiating ...
April 2013
... Of activities aimed at promoting disease education and awareness as a part of comprehensive efforts to eliminate lymphatic filariasis. In addition, the group has formed partnerships with a wide range ...
» Purchase Premium Reports
(From $ 125 - $ 6 995)
About 600 reports
- $ 6 995
- Industry report
- February 2013
- by Global Data
Viviant/Combriza (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Viviant/Combriza (Osteoporosis) - Forecast and Market ...
February 2013
$ 6 995
Protelos (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Protelos (Osteoporosis) - Forecast and Market Analysis to 2022?. ...
February 2013
$ 6 995
BA-058 (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?BA-058 (Osteoporosis) - Forecast and Market Analysis to 2022?. ...
February 2013
$ 6 995
Evista (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Evista (Osteoporosis) - Forecast and Market Analysis to 2022?. ...
February 2013
$ 6 995
Forteo (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Forteo (Osteoporosis) - Forecast and Market Analysis to 2022?. ...
February 2013
$ 6 995
Odanacatib (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Odanacatib (Osteoporosis) - Forecast and Market Analysis ...
February 2013
$ 6 995
Reclast (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Reclast (Osteoporosis) - Forecast and Market Analysis to 2022?. ...
